Malaria is the most lethal parasitic disease in the world. The frequent emergence of resistance by malaria parasites to any drug is the hallmark of sustained malaria burden. Since the deployment of artemisinin-based combination therapies (ACTs) it is clear that for a sustained fight against malaria, drug combination is one of the strategies toward malaria elimination. In Sub-Saharan Africa where malaria prevalence is the highest, the identification of plants with a novel mechanism of action that is devoid of cross-resistance is a feasible strategy in drug combination therapy. Thus, artemether and lumefantrine were separately combined and tested with extracts of , a plant widely used to treat malaria, at fixed extract-drug ratios of 4:1, 3:1, 1:1, 1:2, 1:3, and 1:4. These combinations were tested for antiplasmodial activity against three strains of (W2, D6, and DD2), and seven field isolates that were characterized for molecular and ex vivo drug resistance profiles. The mean sum of fifty-percent fractional inhibition concentration (FIC) of each combination and singly was determined. Synergism was observed across all fixed doses when roots extracts were combined with artemether against D6 strain (FIC 0.403 ± 0.068) and stems extract combined with lumefantrine against DD2 strain (FIC 0.376 ± 0.096) as well as field isolates (FIC 0.656 ± 0.067). Similarly, synergism was observed in all ratios when leaves extract were combined with lumefantrine against W2 strain (FIC 0.456 ± 0.165). Synergism was observed in most combinations indicating the potential use of in combination with artemether and lumefantrine in combating resistance.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8747340PMC
http://dx.doi.org/10.3390/plants11010047DOI Listing

Publication Analysis

Top Keywords

artemether lumefantrine
12
synergism observed
12
strain fic
12
drug combination
8
field isolates
8
extract combined
8
combined lumefantrine
8
malaria
7
combination
6
lumefantrine
5

Similar Publications

We report two cases of recurrent malaria in U.S. travelers returning from Africa (Ghana and Central African Republic) despite a full course of artemether-lumefantrine (AL).

View Article and Find Full Text PDF
Article Synopsis
  • Malaria has surged in sub-Saharan Africa due to disruptions from the Covid-19 pandemic, leading to severe cases like cerebral malaria and acute kidney injury.
  • A 22-year-old male from Chad, who presented with confusion and had a history of travel to an endemic area, was initially misdiagnosed but later confirmed to have malaria with severe symptoms.
  • Successful treatment included intravenous artesunate and hemodialysis, and the patient was discharged after 20 days, highlighting the need for quick diagnosis and effective management of malaria complications.
View Article and Find Full Text PDF

Vitamin C co-administration with artemether-lumefantrine abrogates chronic stress exacerbated Plasmodium berghei-induced sickness behaviour, inflammatory and oxidative stress responses in mice.

J Neuroimmunol

December 2024

Department of Pharmacology and Therapeutics, Faculty of Basic Medical Sciences, University of Ibadan, Ibadan, Oyo-State, Nigeria; Institute of Advanced Medical Research and Training (IAMRAT), College of Medicine, University of Ibadan, Ibadan, Oyo-State, Nigeria.

This study evaluated the effects of vitamin C and artemether-lumefantrine (AL) on sickness behaviour and oxido-inflammatory response in chronically stressed mice infected with Plasmodium berghei. Sickness behaviour severity was examined with weight and assessment of mice behaviours. Results showed that stress increased parasitaemia in infected mice.

View Article and Find Full Text PDF

Malaria remains a significant global health challenge, particularly in endemic regions of Africa, with being the most virulent species. This case report details the presentation of a 24-year-old Caucasian woman who collapsed at a train station in the United Kingdom after experiencing a week of fever, malaise, abdominal pain, and gastrointestinal symptoms. At emergency care, she was initially resuscitated with intravenous fluids and antipyretics.

View Article and Find Full Text PDF

Background: Triple artemisinin-based combination therapies (TACTs) can delay the spread of antimalarial drug resistance. Artesunate-amodiaquine is widely used for uncomplicated Plasmodium falciparum malaria. We therefore aimed to determine the safety and efficacy of artemether-lumefantrine-amodiaquine and artesunate-amodiaquine with and without single low-dose primaquine for reducing gametocyte carriage and transmission to mosquitoes.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!